Cipher Pharmaceuticals Inc T.CPH

Alternate Symbol(s): CPHRF

Healthcare Biotechnology

Cipher Pharmaceuticals Inc. is a specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products, mainly in dermatology. The Company acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products in Canada, the United States, and South America. Its dermatology products include Actikerall, Epuris, and Vaniqa. Its hospital acute care products include Aggrastat and Brinavess. Its out-licensed products include Absorica, ConZip and Lipofen. Durela is its specialty medicine. Its product pipeline includes MOB-015, CF-101, and DTR-001. It delivers novel products to healthcare professionals and patients in Canada in a range of therapeutic areas, including dermatology, women’s health, urology and others. It also has the Natroba operations and global product rights to Natroba and its authorized generic Spinosad, a topical treatment for both head lice and scabies.

TSX:CPH - Post by User

Cipher Pharmaceuticals Inc

Bullboard Posts

Post by ok2buyon Apr 09, 2019 5:28pm

112 Views

Post# 29603898

TD Action Notes Summary

TD Summary published end of March/19 with notes from Lennox Gibbs has CPH listed as a "Hold" with a price target of $2.00. His opinion only. I will continue to buy on weakness as this is a good pharma play. Lots of products coming up in the pipeline. Increasing revenue going into 2020. Best of luck to the longs./ok2

Bullboard Posts

Eminent acquires promising Nevada gold project